Fig 1.
Flow chart of the patients enrolled.
Table 1.
Baseline characteristics of the HCC population, according to the modified BCLC stage.
Table 2.
Distribution of patients and treatment options.
(N = 1801).
Fig 2.
Overall survival curves according to modified BCLC staging system.
BCLC 0 vs. A, p = 0.001; 0 vs. B, p < 0.001; 0 vs. C, p < 0.001; 0 vs. D, p < 0.001; A vs. B, p < 0.001; A vs. C, p < 0.001; A vs. D, p < 0.001; B vs. C, p < 0.001; B vs. D, p < 0.001; C vs. D, p = 0.015.
Fig 3.
A. Overall survival curves in BCLC 0 patients, according to received treatment. Solid line = Treatment according to BCLC recommendation, median survival 81.1 months (95% CI = 63.9- not available). Dotted line = Downward treatment stage migration. median survival 73.0 months (95%- CI = 55.1-not available). B. Overall survival curves in modified BCLC A patients, according to received treatment. Solid line = Treatment according to BCLC recommendation, median survival 73.0 months (95% CI = 67.8–74.9). Dotted line = Downward treatment stage migration. median survival 45.8 months (95% C I = 36.0–57.1). C. Overall survival curves in modified BCLC B patients, according to received treatment. Dashed line = upward treatment stage migration, median survival 81.1 months (95% CI = 44.8- not available). Solid line = Treatment according to BCLC recommendation, median survival 28.2 months (95% CI = 23.0–36.0). Dotted line = downward treatment stage migration, median survival 15.9 months (95% CI = 1.0–25.0). Upward treatment vs. recommended, p = 0.001; Upward treatment vs. downward, p < 0.001; recommended treatment vs. downward, p = 0.001. D. Overall survival curves in modified BCLC C patients, according to received treatment. Dashed line = upward treatment stage migration, median survival 24.0 months (95% CI = 19.1–30.1). Solid line = Treatment according to BCLC recommendation, median survival 6.1 months (95% CI = 4.9–8.1). Dotted line = downward treatment stage migration, median survival 4.2 months (95% CI = 3.2–5.9). Upward treatment vs. recommended, p < 0.001; Upward treatment vs. downward, p < 0.001; recommended treatment vs. downward, p = 0.812. E. Overall survival curves in modified BCLC D patients, according to received treatment. Dashed line = upward treatment stage migration, median survival not reached (95% CI = 40.9-not available). Solid line = Treatment according to BCLC recommendation, median survival 2.9 months (95% CI = 2.0–3.2).
Table 3.
Characteristics of patients with adherence and non-adherence to BCLC guidelines recommendation in BCLC stage 0.
Table 4.
Characteristics of patients with adherence and non-adherence to BCLC guidelines recommendation in BCLC stage A.
Table 5.
Characteristics of patients with adherence and non-adherence to BCLC guidelines recommendation in BCLC stage B.
Table 6.
Characteristics of patients with adherence and non-adherence to BCLC guidelines recommendation in BCLC stage C.
Table 7.
Characteristics of patients with adherence and non-adherence to BCLC guidelines recommendation in BCLC stage D.
Table 8.
Univariate and multivariate analysis of overall survival in BCLC stage 0.
Table 9.
Univariate and multivariate analysis of overall survival in BCLC stage A.
Table 10.
Univariate and multivariate analysis of overall survival in BCLC stage B.
Table 11.
Univariate and multivariate analysis of overall survival in BCLC stage C.
Table 12.
Univariate and multivariate analysis of overall survival in BCLC stage D.